Search Results - "Bjøro, K."

Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy by DALGARD, O., BJØRO, K., HELLUM, K., MYRVANG, B., BJØRO, T., HAUG, E., BELL, H.

“… Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H (Aker University Hospital, Oslo; National Hospital, Oslo; Akershus Central Hospital,…”
Get full text

Short-term treatment duration for HCV-2 and HCV-3 infected patients by Andriulli, A., Dalgard, O., Bjøro, K., Mangia, A.

“…We have shown that 12–14 weeks treatment is effective in HCV-2 or -3 patients with undetectable HCV-RNA after 4 weeks of therapy (rapid virologic response). To…”
Get full text

Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up by Dalgard, O, Bjøro, K, Hellum, K, Myrvang, B, Skaug, K, Gutigard, B, Bell, H

“…To assess the long-term hepatitis C (HCV) treatment outcome in former injecting drug users (IDUs). A long-term follow-up of 27 former IDUs who had been…”
Get more information

412 THE USEFULNESS OF DEFINING RVR BY A VERY SENSITIVE ASSAY DURING THE TREATMENT OF HCV GENOTYPE 3 INFECTION; A COMPARISON OF TMA AND AMPLICOR by Dalgard, O, Martinot-Peignoux, M, Holberg-Petersen, M, Skaug, K, Verbaan, H, Ring-Larsen, H, Bjøro, K, Marcellin, P

Get full text

1151 GENETIC VARIANTS AT ITPA THE LOCUS PROTECTS AGAINST RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA – A REPLICATION STUDY IN A SCANDINAVIAN HCV G2/G3 COHORT by Eskesen, A, Melum, E, Moghaddam, A, Bjøro, K, Verbaan, H, Ring-Larsen, H, Dalgard, O

Get full text

P1093: A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED‐STAGE HODGKIN LYMPHOMA by Rask Kragh Jørgensen, R., Eloranta, S., Tang Severinsen, M., Kiesbye Øvlisen, A., Bjøro Smeland, K., Kiserud, C., Haaber Christensen, J., Hutchings, M., Bo‐Dahl Sørensen, R., Kamper, P., Glimelius, I., Smedby, K. E., Bergström, F., El‐Galaly, T. C., Hjort Jakobsen, L.

Get full text

Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia by BjØro, K., Skaug, K., Haaland, T., FrØland, S.S.

“…The clinical course of HCV infection in patients with primary hypogammaglobulinaemia appears to be more severe than in immunocompetent patients. We studied the…”
Get full text

Treatment with Interferon-Alpha2a Alone or Interferon-Alpha2a plus Ribavirin in Patients with Chronic Hepatitis C Previously Treated with Interferon-Alpha2a by BELL, H, HELLUM, K, RAKNERUD, N, SIMMONDS, P, HARTHUG, S, MYRVANG, B, RITLAND, S, MAELAND, A, VON DER LIPPE, B, BJØRO, K, SKAUG, K, GUTIGARD, B. G

“…Background: Preliminary results from combination therapy with interferon-alpha and ribavirin (IFN/Rib) in patients with chronic hepatitis C have been…”
Get full text

The spectrum of hepatobiliary disease in primary hypogammaglobulinaemia by Bjøro, K., Haaland, T., Skaug, K., Frøland, S. S.

“… Objective.  To study the prevalence of hepatobiliary disease in a clinically and immunologically well‐characterized group of 88 adult Norwegian patients with…”
Get full text

Secondary Osteoporosis in Liver Transplant Recipients: a Longitudinal Study in Patients With and Without Cholestatic Liver Disease by Bjøro, K., Brandsæter, B., Wiencke, K., Bjøro, T., Godang, K., Bollerslev, J., Schrumpf, E.

“…Background: Metabolic bone disease is one of the major long-term complications in liver transplant recipients, but it remains unclear which patients are at…”
Get full text

Topiramate and fulminant liver failure by Bjøm, Kristian, Gjerstad, Leif, Bentdal, Øystein, Osnes, Svein, Schrumpf, Erik

“…Bjoro et al recommend the monitoring of liver function during treatment with topiramate, especially after dose increases…”
Get full text

Variation of Hepatitis C Virus Hypervariable Region 1 in Immunocompromised Patients by Odeberg, Jacob, Yun, Zhibing, Sönnerborg, Anders, Bjøro, Kristian, Uhlén, Mathias, Lundeberg, Joakim

“…The viral variability of 5 hepatitis C virus (HCV)-infected immunocompromised patients was analyzed and compared with that in isolates from immunocompetent…”
Get full text

TT virus infection in patients with primary hypogammaglobulinaemia: Natural history and relationship to liver disease in the immunocompromised host by BJØRO, K, PETROVA, E. P, THOMAS, M. G, FRØLAND, S. S, WILLIAMS, R, NAOUMOV, N. V

“…TT virus (TTV) is a recently discovered human DNA virus with worldwide distribution, but with no clear disease association. The possibility of an enhanced TTV…”
Get full text

TT Virus Infection in Patients with Primary Hypogammaglobulinaemia: Natural History and Relationship to Liver Disease in the Immunocompromised Host by K. Bjøro, E. P. Petrova, M. G. Thomas, S. S. Frøland, R. Williams, N. V. Naoumov

“…Background: TT virus (TTV) is a recently discovered human DNA virus with worldwide distribution, but with no clear disease association. The possibility of an…”
Get full text

Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries by Brandsæter, B., Friman, S., Broomé, U., Isoniemi, H., Olausson, M., Bäckman, L., Hansen, B., Schrumpf, E., Oksanen, A., Ericzon, B.-G., Höckerstedt, K., Mäkisalo, H., Kirkegaard, P., Bjøro, K.

“…Background: Primary sclerosing cholangitis (PSC) is the most common indication for liver transplantation in the Nordic countries. Because these patients are…”
Get full text

Hepatitis C Infection in Patients with Primary Hypogammaglobulinemia after Treatment with Contaminated Immune Globulin by Bjoro, Kristian, Froland, Stig S, Yun, Zhibing, Samdal, Helvi H, Haaland, Terese

“…Non-A, non-B hepatitis has been reported after substitution therapy with immune globulin in several patients with primary hypogammaglobulinemia 1 – 6 . In…”
Get full text

Effect of Combined Interferon-α Induction Therapy and Ribavirin on Chronic Hepatitis C Virus Infection: a Randomized Multicentre Study by Bjøro, K., Bell, H., Hellum, K. B., Skaug, K., Raknerud, N., Sandvei, P., Døskeland, B., Maeland, A., Lund-Tønnesen, S., Myrvang, B.

“…Background: The efficacy of interferon- α (IFN) induction in combination with ribavirin for chronic hepatitis C virus (HCV) infection is not known. Methods: A…”
Get full text

Monstrous ascites in hereditary haemorrhagic telangiectasia by Bjøro, K, Schrumpf, E, Elgjo, K, Kolmanskog, F

“…Hepatic involvement in hereditary haemorrhagic telangiectasia (HHT) consisting of fibrosis, telangiectases, and cirrhosis, has been reported as a relatively…”
Get more information

Liver transplantation in the Nordic countries, 1982-1998: changes of indications and improving results by Bjøro, K, Friman, S, Höckerstedt, K, Kirkegaard, P, Keiding, S, Schrumpf, E, Olausson, M, Oksanen, A, Isoniemi, H, Hjortrup, A, Bergan, A, Ericzon, B G

“…Liver transplantation has become an established therapeutic option for patients with life-threatening liver disease. The aim of the present study was to…”
Get full text

728 IS SUSTAINED VIROLOGICAL RESPONSE TO HCV TREATMENT ASSOCIATED WITH A CLINICAL IMPORTANT IMPROVEMENT IN VITALITY? by Dalgard, O, BjOro, K, Ring-Larsen, H, Verbaan, H

Get full text